DC Circ. Restarts FTC's Endo Appeal Despite Ch. 11
The D.C. Circuit on Monday resumed briefing on Federal Trade Commission antitrust claims against Endo Pharmaceuticals Inc. after the FTC argued Endo's Chapter 11 filing didn't require the court to halt...To view the full article, register now.
Already a subscriber? Click here to view full article